Centessa Pharmaceuticals Plc Stock Investor Sentiment

CNTA Stock  USD 16.96  0.37  2.23%   
About 58% of all Centessa Pharmaceuticals' investors are looking to take a long position. The analysis of the overall investor sentiment regarding Centessa Pharmaceuticals PLC suggests that some traders are interested. The current market sentiment, together with Centessa Pharmaceuticals' historical and current headlines, can help investors time the market. In addition, many technical investors use Centessa Pharmaceuticals stock news signals to limit their universe of possible portfolio assets.
  

Centessa Pharmaceuticals Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Centessa Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Centessa Pharmaceuticals Maximum Pain Price Across April 17th 2025 Option Contracts

Centessa Pharmaceuticals' options can also be used to analyze investors' bias and current market sentiment in the context of behavioral finance. For example, Max pain usually refers to a trading concept that asserts that market manipulation can cause the market price of Centessa Pharmaceuticals close to the expiration of its current option contract to expire worthlessly. According to most research, about 35% of options are not executed, with roughly 50% traded out before expiration. So, Max pain occurs when market makers reach a net favorable position across all options at a strike price where option holders stand to lose the most money. By contrast, option sellers may reap the most after selling more options than buying, causing them to expire worthlessly. Please continue to view the detailed analysis of Centessa Pharmaceuticals' options.
2 days ago at news.google.com         
Insider Selling Centessa Pharmaceuticals plc Insider Sells 11,742 Shares of Stock - MarketBeat
Google News at Macroaxis
3 days ago at news.google.com         
Centessa Pharmaceuticals chief business officer sells shares worth 193,429 - Investing.com
Google News at Macroaxis
few days ago at www.macroaxis.com         
Disposition of 11742 shares by Weinhoff Gregory M of Centessa Pharmaceuticals at 16.4733 subject to ...
Macroaxis News
over a week ago at news.google.com         
Insider Selling Centessa Pharmaceuticals plc CEO Sells 55,000 Shares of Stock - MarketBeat
Google News at Macroaxis
over a week ago at thelincolnianonline.com         
Disposition of 1625 shares by Saha Saurabh of Centessa Pharmaceuticals at 16.1937 subject to Rule 16...
news
over a week ago at news.google.com         
Centessa Pharmaceuticals plc General Counsel Sells 91,740.00 in Stock - MarketBeat
Google News at Macroaxis
over two weeks ago at www.macroaxis.com         
Disposition of 87496 shares by Saha Saurabh of Centessa Pharmaceuticals at 5.84 subject to Rule 16b-...
Macroaxis News
over two weeks ago at www.macroaxis.com         
Disposition of 6000 shares by Hussain Iqbal J of Centessa Pharmaceuticals at 15.29 subject to Rule 1...
Macroaxis News
over two weeks ago at news.google.com         
Trading Signals - Stock Traders Daily
Google News at Macroaxis
over two weeks ago at finance.yahoo.com         
Why Is Centessa Pharmaceuticals Among the Best Medical Stocks to Buy Under 20?
Yahoo News
over two weeks ago at finance.yahoo.com         
Is Centessa Pharmaceuticals plc the Best Growth Stock to Buy Now Under 25?
Yahoo News
over two weeks ago at insidermonkey.com         
Is Centessa Pharmaceuticals plc the Best Growth Stock to Buy Now Under 25?
insidermonkey News
over three weeks ago at gurufocus.com         
Centessa Pharmaceuticals Appoints New Chief Medical Officer to Advance OX2R Agonist Portfolio
Gurufocus Stories at Macroaxis
over three weeks ago at gurufocus.com         
Centessa Pharmaceuticals Announces Appointment of Stephen Kanes, MD PhD, as Chief Medical Officer
Gurufocus Stories at Macroaxis
over three weeks ago at www.macroaxis.com         
Insider Trading
Macroaxis News
Far too much social signal, news, headlines, and media speculation about Centessa Pharmaceuticals that are available to investors today. That information is available publicly through Centessa media outlets and privately through word of mouth or via Centessa internal channels. However, regardless of the origin, that massive amount of Centessa data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Centessa Pharmaceuticals news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Centessa Pharmaceuticals relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Centessa Pharmaceuticals' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Centessa Pharmaceuticals alpha.

Centessa Pharmaceuticals Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Disposition of 32023 shares by Saha Saurabh of Centessa Pharmaceuticals at 18.2812 subject to Rule 16b-3
11/13/2024
2
Disposition of 55000 shares by Saha Saurabh of Centessa Pharmaceuticals at 16.8858 subject to Rule 16b-3
11/20/2024
3
Disposition of 87496 shares by Saha Saurabh of Centessa Pharmaceuticals at 18.4609 subject to Rule 16b-3
12/06/2024
4
Disposition of 5876 shares by Karen Anderson of Centessa Pharmaceuticals at 3.85 subject to Rule 16b-3
12/13/2024
5
Disposition of 10624 shares by Karen Anderson of Centessa Pharmaceuticals at 3.85 subject to Rule 16b-3
12/17/2024
6
Disposition of 10000 shares by Weinhoff Gregory M of Centessa Pharmaceuticals at 3.85 subject to Rule 16b-3
12/26/2024
7
Disposition of 6419 shares by Tia Bush of Centessa Pharmaceuticals at 16.35 subject to Rule 16b-3
12/31/2024
8
Centessa Pharmaceuticals plc Receives 25.83 Consensus Target Price from Brokerages
01/02/2025
9
Insider Trading
01/06/2025
10
Centessa Pharmaceuticals Announces Appointment of Stephen Kanes, MD PhD, as Chief Medical Officer
01/08/2025
11
Why Is Centessa Pharmaceuticals Among the Best Medical Stocks to Buy Under 20
01/13/2025
12
Disposition of 6000 shares by Hussain Iqbal J of Centessa Pharmaceuticals at 15.29 subject to Rule 16b-3
01/15/2025
13
Disposition of 87496 shares by Saha Saurabh of Centessa Pharmaceuticals at 5.84 subject to Rule 16b-3
01/16/2025
14
Insider Selling Centessa Pharmaceuticals plc CEO Sells 55,000 Shares of Stock - MarketBeat
01/23/2025
15
Disposition of 11742 shares by Weinhoff Gregory M of Centessa Pharmaceuticals at 16.4733 subject to Rule 16b-3
01/27/2025
16
Insider Selling Centessa Pharmaceuticals plc Insider Sells 11,742 Shares of Stock - MarketBeat
01/29/2025

Complementary Tools for Centessa Stock analysis

When running Centessa Pharmaceuticals' price analysis, check to measure Centessa Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Centessa Pharmaceuticals is operating at the current time. Most of Centessa Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Centessa Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Centessa Pharmaceuticals' price. Additionally, you may evaluate how the addition of Centessa Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Fundamental Analysis
View fundamental data based on most recent published financial statements
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Stocks Directory
Find actively traded stocks across global markets